These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 6849772)

  • 1. No significant effect of metoclopramide on misonidazole elimination in man.
    Williams KM; Begg EJ; Wade DN; O'Shea K
    Br J Clin Pharmacol; 1983 Mar; 15(3):390-2. PubMed ID: 6849772
    [No Abstract]   [Full Text] [Related]  

  • 2. No significant effect of cimetidine on the pharmacokinetics of misonidazole in man.
    Begg EJ; Williams KM; Wade DN; O'Shea KF
    Br J Clin Pharmacol; 1983 May; 15(5):575-6. PubMed ID: 6860535
    [No Abstract]   [Full Text] [Related]  

  • 3. Kinetics of misonidazole enantiomers.
    Williams KM
    Clin Pharmacol Ther; 1984 Dec; 36(6):817-23. PubMed ID: 6499361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of phenytoin, phenobarbital, and ascorbic acid on misonidazole elimination.
    Williams K; Begg E; Wade D; O'Shea K
    Clin Pharmacol Ther; 1983 Mar; 33(3):314-21. PubMed ID: 6825387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biliary and faecal excretion of misonidazole in man.
    Ash DV; Smith MR
    Br J Radiol; 1979 Oct; 52(622):846-8. PubMed ID: 509037
    [No Abstract]   [Full Text] [Related]  

  • 6. Kinetic aspects of misonidazole and its major metabolite in radiotherapy.
    Meering PG; Gonzalez DG; Maes RA; van Peperzeel HA
    Hum Toxicol; 1985 Jul; 4(4):425-34. PubMed ID: 4018823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circadian changes in the elimination of misonidazole in mouse.
    Labat C; Malmary MF; Casanovas AM; Patau JP; Oustrin J
    Res Commun Chem Pathol Pharmacol; 1983 Nov; 42(2):331-4. PubMed ID: 6658193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of dexamethasone in the modification of misonidazole pharmacokinetics.
    Jones DH; Bleehen NM; Workman P; Walton MI
    Br J Cancer; 1983 Oct; 48(4):553-7. PubMed ID: 6626454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenytoin sodium-induced alterations in the pharmacokinetics of misonidazole in the dog.
    White RA; Workman P
    Cancer Treat Rep; 1980; 64(2-3):360-1. PubMed ID: 7190871
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of cimetidine, antipyrine, and pregnenolone carbonitrile on misonidazole pharmacokinetics.
    Workman P; Donaldson J; Smith NC
    Cancer Treat Rep; 1983; 67(7-8):723-5. PubMed ID: 6871889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenytoin-misonidazole: possible metabolic interaction.
    Gangji D; Schwade JG; Strong JM
    Cancer Treat Rep; 1980 Jan; 64(1):155-6. PubMed ID: 7379050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic considerations of misonidazole in therapeutics.
    Matheson I; Plowman PN; Johnston A
    Hum Toxicol; 1984 Feb; 3(1):29-36. PubMed ID: 6698564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetics of misonidazole in the dog.
    White RA; Workman P; Freedman LS; Owen LN; Bleehen NM
    Eur J Cancer (1965); 1979 Oct; 15(10):1233-42. PubMed ID: 520395
    [No Abstract]   [Full Text] [Related]  

  • 14. Structure-pharmacokinetic relationships for misonidazole analogues in mice.
    Workman P; Brown JM
    Cancer Chemother Pharmacol; 1981; 6(1):39-49. PubMed ID: 7273265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The metabolism and pharmacokinetics of the hypoxic cell radiosensitizer and cytotoxic agent, misonidazole, in C3H mice.
    Chin JB; Rauth AM
    Radiat Res; 1981 May; 86(2):341-57. PubMed ID: 7232696
    [No Abstract]   [Full Text] [Related]  

  • 16. Phenytoin-induced changes in the pharmacokinetics of misonidazole in radiotherapy patients.
    Moore JL; Paterson IC; Newman H; Venables S
    Br J Cancer; 1981 Oct; 44(4):592-6. PubMed ID: 7295516
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacokinetics of the hypoxic radiosensitizers misonidazole and demethylmisonidazole after intraperitoneal administration in humans.
    Gianni L; Jenkins JF; Greene RF; Lichter AS; Myers CE; Collins JM
    Cancer Res; 1983 Feb; 43(2):913-6. PubMed ID: 6848201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reductive fragmentation of 2-nitroimidazoles in the presence of nitroreductases--glyoxal formation from misonidazole.
    Raleigh JA; Liu SF
    Biochem Pharmacol; 1983 Apr; 32(8):1444-6. PubMed ID: 6687998
    [No Abstract]   [Full Text] [Related]  

  • 19. Absorption and distribution of vaginally administered misonidazole.
    Ash D; Bugden R; Calvert R
    Cancer Chemother Pharmacol; 1982; 9(2):118-9. PubMed ID: 7172406
    [No Abstract]   [Full Text] [Related]  

  • 20. The pharmacokinetics and tumor and neural tissue penetrating properties of SR-2508 and SR-2555 in the dog--hydrophilic radiosensitizers potentially less toxic than misonidazole.
    White RA; Workman P; Brown JM
    Radiat Res; 1980 Dec; 84(3):542-61. PubMed ID: 6450431
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.